Vincent Ling

Dr Ling is Chief Business Officer at Morphocell, a biotech start-up company developing regenerative technologies for the treatment of liver disease.

For over 30 years, Dr Ling has led successful research and business innovation groups in diverse biotechnology fields, including cell devices, protein engineering, biosimilars, stem cell differentiation, checkpoint inhibitors, and the molecular evolution of antibody scaffolds. He has held leadership positions in large, midsized, and start-up environments, creating practical biotherapeutics.

Dr Ling recently stepped down as Senior Director within Search and Evaluation, Business Development at Takeda after directorship roles in external innovation and pharmaceutical sciences. His current interests lie in novel drug delivery technologies, including drug particles, energy guidance, and biomaterial scaffolds. In his new appointment as Chief Business Officer at Morphocell, he represents the company in the Boston BioPharma ecosystem.

Prior to Takeda, Dr Ling was Head of Biological Sciences, developing cell therapies for wet AMD at Neurotech.  He has held positions including Vice President at Dragonfly Sciences, managing all scientific operations and marketing functions, Director of Molecular Genetics at Adnexus (Compound Therapeutics), and other scientific roles in Discovery Research at Genetics Institute and Wyeth Pharmaceuticals.